Ep. 256, Chapter 5: The atai Life Sciences Approach With Srinivas Rao

29:46 – 41:31

atai began with a broad hub-and-spoke model, combining internal drug development with strategic investments in Beckley Psytech and Recognify Life Sciences to diversify its pipeline and address unmet needs in mental health. After disappointing clinical results with their PCN-101 (R-ketamine) therapy, atai streamlined its operations to focus on fewer assets with high potential, particularly short-duration psychedelics that align with existing clinical infrastructure. Over the next year, the company anticipates four key Phase 2 readouts which will be critical in shaping its next phase of growth.